BR0210586A - Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas - Google Patents

Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas

Info

Publication number
BR0210586A
BR0210586A BR0210586-1A BR0210586A BR0210586A BR 0210586 A BR0210586 A BR 0210586A BR 0210586 A BR0210586 A BR 0210586A BR 0210586 A BR0210586 A BR 0210586A
Authority
BR
Brazil
Prior art keywords
inducing
methods
simian adenovirus
immune reaction
cytotoxic immune
Prior art date
Application number
BR0210586-1A
Other languages
English (en)
Inventor
Hildegund C J Ertl
James M Wilson
Original Assignee
Wistar Inst
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst, Univ Pennsylvania filed Critical Wistar Inst
Publication of BR0210586A publication Critical patent/BR0210586A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODOS PARA INDUZIR UMA REAçãO IMUNE CITOTóXICA E COMPOSIçõES DE ADENOVìRUS DE SìMIO RECOMBINANTE úTEIS DAS MESMAS". é proporcionado um método para induzir uma reação de T CD8+ contra uma molécula selecionada liberando a molécula através de um adenovírus de símio recombinante. Também são proporcionados métodos para induzir interferon-<244> e interferon-<255> liberando um adenovírus de símio recombinante para um paciente. Os métodos e composições da invenção são particularmente adequados para profilaxia e tratamento de infecções com vírus da imunodeficiência humana e papiloma vírus humano, entre outras, e terapia do câncer.
BR0210586-1A 2001-06-22 2002-05-13 Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas BR0210586A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30013101P 2001-06-22 2001-06-22
US30484301P 2001-07-12 2001-07-12
PCT/US2002/015239 WO2003000283A1 (en) 2001-06-22 2002-05-13 Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein

Publications (1)

Publication Number Publication Date
BR0210586A true BR0210586A (pt) 2005-07-12

Family

ID=26971607

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210586-1A BR0210586A (pt) 2001-06-22 2002-05-13 Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas

Country Status (26)

Country Link
US (1) US20040241181A1 (pt)
EP (1) EP1409012B1 (pt)
JP (1) JP2005523233A (pt)
KR (1) KR20040043129A (pt)
CN (1) CN1518457A (pt)
AT (1) ATE422365T1 (pt)
AU (1) AU2002308713B2 (pt)
BR (1) BR0210586A (pt)
CA (1) CA2451864C (pt)
CY (1) CY1109059T1 (pt)
CZ (1) CZ304169B6 (pt)
DE (1) DE60231123D1 (pt)
DK (1) DK1409012T3 (pt)
ES (1) ES2322043T3 (pt)
HK (1) HK1061511A1 (pt)
HU (1) HU228327B1 (pt)
IL (2) IL159454A0 (pt)
MX (1) MXPA04000024A (pt)
NO (1) NO333252B1 (pt)
NZ (1) NZ530245A (pt)
PL (1) PL216200B1 (pt)
PT (1) PT1409012E (pt)
SG (1) SG153649A1 (pt)
SI (1) SI1409012T1 (pt)
WO (1) WO2003000283A1 (pt)
ZA (1) ZA200309360B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
BR0214350A (pt) * 2001-11-21 2005-05-10 Univ Pennsylvania Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
ES2478625T3 (es) * 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
CN107723298A (zh) 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
CN101384722A (zh) * 2005-05-12 2009-03-11 葛兰素集团有限公司 疫苗组合物
KR20090094213A (ko) 2006-07-18 2009-09-04 글락소스미스클라인 바이오로지칼즈 에스.에이. 말라리아 백신
BRPI0808553A2 (pt) 2007-03-02 2014-08-19 Glaxosmithkline Biolog Sa Métodos para elevar uma resposta imune contra um patógeno, para estimar a produção de células t cd4+ e/ou cd8+ e/ou anticorpos específicos de patógeno em mamíferos e para estimular uma resposta imune em um mamífero, composição de vacina, uso da mesma, e, kit
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
DK2220242T3 (en) * 2007-11-28 2017-03-27 Univ Pennsylvania ABE-ADENOVIRA OF GROUP B, SADV-28,27, -29, -32, -33 AND -35 AND APPLICATIONS THEREOF
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2011057254A2 (en) * 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2011133870A2 (en) * 2010-04-22 2011-10-27 Andrea Amalfitano Vaccines comprising adenovirus vectors and signaling lymphocyte activating molecule-associated protein (sap)
CN102060915A (zh) * 2010-10-29 2011-05-18 广州呼吸疾病研究所 人3型腺病毒六邻体的可修饰位点及其应用
KR20220047790A (ko) * 2011-03-21 2022-04-19 알티뮨 인크. 급속 및 지속적 면역학적제제-치료제
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
CN103937835A (zh) * 2013-08-19 2014-07-23 中国科学院上海巴斯德研究所 一种基于腺病毒AdC68的表达载体及其构建方法
CN103468743B (zh) * 2013-08-19 2015-07-29 中国科学院上海巴斯德研究所 一种狂犬病疫苗及其制备方法
DK3062815T3 (en) 2013-11-01 2019-03-11 Pfizer Vectors for expression of prostate-associated antigens
ES2714921T3 (es) 2014-05-19 2019-05-30 Valo Therapeutics Oy Adenovirus oncolíticos recubiertos para vacunas contra el cáncer
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
US11254711B2 (en) 2015-06-12 2022-02-22 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3551644B1 (en) * 2016-12-09 2023-08-16 GlaxoSmithKline Biologicals SA Chimpanzee adenovirus constructs with lyssavirus antigens
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
WO2019016756A1 (en) 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
CA3077630A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
CN111295391B (zh) 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
MX2020004492A (es) 2017-10-31 2020-11-24 Janssen Vaccines & Prevention Bv Adenovirus y usos de los mismos.
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
CN111801342A (zh) 2017-12-20 2020-10-20 葛兰素史密丝克莱恩生物有限公司 爱泼斯坦-巴尔病毒抗原构建体
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
WO2022013221A1 (en) 2020-07-13 2022-01-20 Transgene Treatment of immune depression
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
AU6261696A (en) * 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6210663B1 (en) * 1998-08-20 2001-04-03 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting

Also Published As

Publication number Publication date
EP1409012A4 (en) 2005-08-03
PL372294A1 (en) 2005-07-11
NO20035740D0 (no) 2003-12-19
DE60231123D1 (de) 2009-03-26
PT1409012E (pt) 2009-05-11
HUP0400297A3 (en) 2010-08-30
PL216200B1 (pl) 2014-03-31
SG153649A1 (en) 2009-07-29
EP1409012A1 (en) 2004-04-21
NO333252B1 (no) 2013-04-22
CZ20033438A3 (cs) 2004-04-14
DK1409012T3 (da) 2009-05-18
CY1109059T1 (el) 2014-07-02
ES2322043T3 (es) 2009-06-16
EP1409012B1 (en) 2009-02-11
CN1518457A (zh) 2004-08-04
MXPA04000024A (es) 2004-05-21
HUP0400297A2 (en) 2007-05-02
NO20035740L (no) 2004-02-16
CA2451864A1 (en) 2003-01-03
IL159454A (en) 2009-09-01
KR20040043129A (ko) 2004-05-22
WO2003000283A1 (en) 2003-01-03
JP2005523233A (ja) 2005-08-04
CZ304169B6 (cs) 2013-12-04
CA2451864C (en) 2013-01-15
US20040241181A1 (en) 2004-12-02
AU2002308713B2 (en) 2008-05-15
ZA200309360B (en) 2005-07-27
HU228327B1 (en) 2013-03-28
SI1409012T1 (sl) 2009-08-31
ATE422365T1 (de) 2009-02-15
HK1061511A1 (en) 2004-09-24
AU2002308713A2 (en) 2003-01-08
IL159454A0 (en) 2004-06-01
NZ530245A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
BR0210586A (pt) Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas
BRPI0416079A (pt) análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
BR0208446A (pt) Agentes terapêuticos para doenças inflamatórias do intestino
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
GEP20074211B (en) Novel perindopril salt and pharmaceutical compositions containing same
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
UY27981A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
CY1106873T1 (el) Συνθεση για φαρμακευτικη χρηση ή για χρηση ως συμπληρωμα διατροφης για την αντιμετωπιση τριχοπτωσης
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
MX2020009150A (es) Anfifilos de cpg y usos de los mismos.
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
BRPI0413481A (pt) cascas de lêvedos para o tratamento ou a prevenção da hiperglicemia ou para a estabilização da glicemia
AP9801286A0 (en) Therapeutic compounds.
BRPI0418224A (pt) composição que compreende um extrato aquoso de folhas de videira-vermelha e um agente antitrombótico para o tratamento de insuficiências venosas crÈnicas
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
GT199900083A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica.
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
DK1143976T3 (da) Beta-D-2&#39;, 3&#39;-didehydro-2&#39;, 3&#39;-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
EA202193151A1 (ru) Режимы дозирования агониста il-2/il-15r для лечения рака или инфекционных заболеваний
MX2022013611A (es) Derivados de alquilaminoprolina como bloqueadores de alfa-2-delta-1.
FR2820979B1 (fr) Nouvelle application therapeutique du g-csf
PT1490049E (pt) Citalopram para o tratamento da pre3ssao sanguinia elevada.
BR9810095A (pt) Dispositivos para distribuição de droga e métodospara tratamento de infecções virais e microbianase de sìndromes de emaciação
AU2003274076A1 (en) Human chondroosteomodulin (tig2), production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL